Genprex
General Information | |
Business: |
Genprex™ is a clinical stage gene therapy company developing a new approach to treating cancer, based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 4 |
Founded: | 2009 |
Contact Information | |
Address | 100 Congress Avenue, Suite 2000 Austin, TX, 78701, US |
Phone Number | (512) 370-4081 |
Web Address | http://www.genprex.com |
View Prospectus: | Genprex |
Financial Information | |
Market Cap | $65.2mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-3.6 mil (last 12 months) |
IPO Profile | |
Symbol | GNPX |
Exchange | NASDAQ |
Shares (millions): | 1.3 |
Price range | $5.00 - $5.00 |
Est. $ Volume | $6.4 mil |
Manager / Joint Managers | Network 1 Financial Securities |
CO-Managers | - |
Expected To Trade: | 3/29/2018 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |